Evaluation of Meningococcal C Conjugate Vaccine Programs in Canadian Children

加拿大儿童 C 型脑膜炎球菌结合疫苗计划的评估

• 批准号: 170733
• 负责人: Bettinger Julie A
• 金额: $ 50.97万
• 依托单位: Undetermined
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2008
• 资助国家: 加拿大
• 起止时间: 2008-09-01 至 2013-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=170733&lang=en
• 关键词: Cohort Study; Conjugate Vaccines; Infant Immunization Programs; Meningococcal Disease Prevention; Meningococcal Serogroup C Vaccination

Infections with meningococcal bacteria are rare but cause serious, fatal illness. Young children ages 0-5 years are at the highest risk for these infections. Prevention is desirable, as about 15% of infected persons die, and another 15% suffer permanent

脑膜炎球菌感染很罕见，但会导致严重的致命疾病。 0-5岁的幼儿感染这些疾病的风险最高。 预防是可取的，因为大约15%的感染者死亡，另外15%的人遭受永久性的痛苦。